These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34466802)

  • 1. Erratum to:
    JAC Antimicrob Resist; 2021 Sep; 3(3):dlab109. PubMed ID: 34466802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erratum to:
    JAC Antimicrob Resist; 2021 Sep; 3(3):dlab110. PubMed ID: 34466803
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Falcone M
    JAC Antimicrob Resist; 2021 Jun; 3(Suppl 1):i25. PubMed ID: 34223153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compassionate use of cefiderocol for carbapenem-resistant
    Mabayoje DA; NicFhogartaigh C; Cherian BP; Tan MGM; Wareham DW
    JAC Antimicrob Resist; 2021 Jun; 3(Suppl 1):i21-i24. PubMed ID: 34223152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Cefiderocol Against
    Iregui A; Khan Z; Landman D; Quale J
    Microb Drug Resist; 2020 Jul; 26(7):722-726. PubMed ID: 32031915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vitro Antimicrobial Activity of the Siderophore Cephalosporin Cefiderocol against
    Carcione D; Siracusa C; Sulejmani A; Migliavacca R; Mercato A; Piazza A; Principe L; Clementi N; Mancini N; Leoni V; Intra J
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection.
    Candel FJ; Santerre Henriksen A; Longshaw C; Yamano Y; Oliver A
    Clin Microbiol Infect; 2022 Mar; 28(3):447.e1-447.e6. PubMed ID: 34298176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens.
    Jorda A; Zeitlinger M
    Expert Rev Clin Pharmacol; 2021 Jul; 14(7):777-791. PubMed ID: 33849355
    [No Abstract]   [Full Text] [Related]  

  • 10. Cefiderocol: A Siderophore Cephalosporin.
    El-Lababidi RM; Rizk JG
    Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case Report: Successful Rescue Therapy of Extensively Drug-Resistant
    Dagher M; Ruffin F; Marshall S; Taracila M; Bonomo RA; Reilly R; Fowler VG; Thaden JT
    Open Forum Infect Dis; 2020 May; 7(5):ofaa150. PubMed ID: 32494581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Perspectives on Antimicrobial Agents: Cefiderocol.
    McCreary EK; Heil EL; Tamma PD
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0217120. PubMed ID: 34031052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cefiderocol-Based Combination Therapy for "Difficult-to-Treat" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives.
    Bavaro DF; Belati A; Diella L; Stufano M; Romanelli F; Scalone L; Stolfa S; Ronga L; Maurmo L; Dell'Aera M; Mosca A; Dalfino L; Grasso S; Saracino A
    Antibiotics (Basel); 2021 May; 10(6):. PubMed ID: 34072342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cefiderocol: a novel siderophore cephalosporin against multi-drug resistant Gram-negative bacilli infections].
    Kuai J; Wang X; Wang H
    Sheng Wu Gong Cheng Xue Bao; 2022 Mar; 38(3):990-1003. PubMed ID: 35355469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study.
    Bleibtreu A; Dortet L; Bonnin RA; Wyplosz B; Sacleux SC; Mihaila L; Dupont H; Junot H; Bunel V; Grall N; Razazi K; Duran C; Tattevin P; Dinh A; The Cefiderocol French Study Group OBO
    Microorganisms; 2021 Jan; 9(2):. PubMed ID: 33573148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of
    Ballesté-Delpierre C; Ramírez Á; Muñoz L; Longshaw C; Roca I; Vila J
    Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively and pan-resistant Acinetobacter baumannii.
    Oliva A; Ceccarelli G; De Angelis M; Sacco F; Miele MC; Mastroianni CM; Venditti M
    J Glob Antimicrob Resist; 2020 Dec; 23():292-296. PubMed ID: 33065329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.